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Abstract 
Methamphetamine (METH) is a powerful psychostimulant drug used worldwide for its 
reinforcing properties. In addition to the classic long-lasting monoaminergic-disrupting effects 
extensively described in the literature, METH has been consistently reported to increase blood 
brain barrier (BBB) permeability, both in vivo and in vitro, as a result of tight junction and 
cytoskeleton disarrangement. Microtubules play a critical role in cell stability, which relies on 
post-translational modifications such as a-tubulin acetylation. As there is evidence that 
psychostimulants drugs modulate the expression of histone deacetylases (HDACs), we 
hypothesized that in endothelial cells METH-mediation of cytoplasmatic HDAC6 activity could 
affect tubulin acetylation and further contribute to BBB dysfunction. To validate our hypothesis, 
we exposed the bEnd.3 endothelial cells to increasing doses of METH and verified that itleads to 
an extensivea-tubulin deacetylation mediated by HDACs activation. Furthermore, since we 
recently reported that acetyl-L-carnitine (ALC), a natural occurring compound, prevents BBB 
structural loss in a context of METH exposure, we reasoned that ALC could also preserve the 
acetylation of microtubules under METH action. The present results confirm that ALC is able to 
prevent METH-induced deacetylation providing effective protection on microtubule acetylation. 
Although further investigation is still needed, HDACs regulation may become a new therapeutic 
target for ALC. 
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1. Introduction Methamphetamine (METH) is a powerful psychostimulant used worldwide 
for its reinforcing properties that leads to long-lasting deleterious effects (Gold et al., 
2009; Krasnova and Cadet, 2009). 
METH toxicity is characterized by the disruption of the dopaminergic system, 
concomitant with terminal degeneration and eventual neuronal death (Conant et al., 
2011; Krasnova and Cadet, 2009). However, METH has been increasingly recognized to 
impact also the blood-brain-barrier (BBB), causing the release of inflammatory 
mediators and astrogliosis (Gold et al., 2009; Goncalves et al., 2010; Northrop and 
Yamamoto, 2012; Ramirez et al., 2009). METH-induced permeability at the BBB level has 
been consistently reported both in vivo and in vitro (Conant et al., 2011; Martins et al., 
2011; Urrutia et al., 2013), as a result of tight junction and cytoskeleton disarrangement 
(Dietrich, 2009; Kousik et al., 2012; Park et al., 2013). In endothelial cells, METH was also 
shown to trigger nitric oxide (NO)-mediated transcytosis (Martins et al., 2013). Recently, 
we showed, also in endothelial cells, that exposure to METH leads to disruption of actin 
filaments concomitant with claudin-5 translocation to the cytoplasm, promoted by 
MMP-9 activation in association with ILK overexpression (Fernandes et al., 2014). 
Similarly to the actin filaments, microtubules play a critical role in cell stability and 
dynamics. Proper regulation of microtubule components relies on post translational 
modifications such as a-tubulin acetylation (Hammond et al., 2008). Microtubule 
deacetylation is carried out by histone deacetylase (HDAC) 6, a class II HDAC and the 
class III HDAC sirtuin 2 (SIRT2), which form a complex that allows them to bind to tubulin 
(Hubbert et al., 2002; Nahhas et al., 2007; Sadoul et al., 2011; Yang and Seto, 2008). Of 
note, it was recently shown that interfering with HDAC6 is sufficient to prevent 
microtubule deacetylation (Gold et al., 2015). There is growing evidence that HDACs 
inhibition is strongly associated with decreased cell mobility, which is of particular 
interest in the oncology field (Hrabeta et al., 2014; Ocker and Schneider-Stock, 2007). 
Although there are several studies showing that METH and other psychostimulants 
affect the expression of HDACs (Cassel et al., 2006; Host et al., 2011; Martin et al., 2012; 
Omonijo et al., 2014), and in particular the expression of HDAC6 (Omonijo et al., 2014), 
the effect of METH in microtubules acetylation was not yet explored. Therefore, we 
hypothesized that METH-induced regulation of HDACs activity, and in particular of 
HDAC6, may also mediate the structural loss observed in METH-exposed endothelial 
cells. Moreover, since we recently showed that a pretreatment with acetyl-L-carnitine 
(ALC) was able to prevent METH-induced activation of MMP-9, preserving the actin 
structural arrangement in the endothelial cells (Fernandes et al., 2014), and ALC was 
shown to have the potential to interact with HDAC activity (Huang et al., 2012), we 
reasoned that ALC could also preserve the acetylation of microtubules under METH 
action. ALC is a natural occurring compound that was seen to be protective by different 
mechanisms in several neurological conditions, including BBB dysfunction (Alves et al., 
2009; Haorah et al., 2011; Muneer et al., 2011; Pettegrew et al., 2000). To verify our 
hypothesis, we exposed the endothelial cell line bEnd.3 to increasing doses of METH and 
evaluated the individual and combined action of METH and ALC on a-tubulin acetylation. 
Trichostatin A (TSA), a natural product isolated from Streptomyces hygroscopicus 
commonly used as an inhibitor of class I/II HDACs known to promote microtubule 
acetylation, was also assayed (Dompierre et al., 2007; Harrison and Dexter, 2013). 
 
2. Material and methods  
 
2.1. In vitro model and cell culture  
The immortalized bEnd.3 cells are derived from mouse brains and known to mimic some 
of the BBB characteristics. The cell line bEnd.3 was obtained from ATCC (American Type 
Cell Culture-CRL- 2299, Manassas, VA) and cultures were maintained in DMEM (1)/ 
Glutamax (GIBCO1, Life Technologies, Paisley, UK), containing 1% penicillin and 
streptomycin (GIBCO1, Life Technologies) and 10% fetal bovine serum (GIBCO1, Life 
Technologies). Purity of the cell line was checked using an anti-CD31 antibody (Abcam 
7388, rat monoclonal, 1:1000), which showed 100% enrichment of cells on the adhesion 
marker. For immunocytochemistry, cells were plated on 24-well plates (80,000 
cells/well) containing glass cover slips. To obtain protein extracts or mRNA, bEnd.3 cells 
were cultured in petri dishes (1 million of cells). Cell culture media was changed every 3 
days until cells were confluent. 
 
2.2. Drug regimen 
ALC-hydrochloride was kindly provided by Sigma-Tau S.p.A (Pomezia, Italy). TSA was 
purchased from Promega (#G6560) and METH hydrochloride from Sigma–Aldrich (St. 
Louis, MO, Cat. M-8750). Immortalized bEnd.3 cells at confluence were treated with 0.5 
mM and 1 mM of METH. METH doses were predetermined in our laboratory in 
agreement with previous studies using METH in similar cell models (Fernandes et al., 
2014; Jin et al., 2002). ALC 1 mM was added 30 min before METH. TSA was used in a 100 
nM concentration. The selected TSA and ALC doses were previously shown to be safe 
for the cells and are below the range of doses previously used in similar works (Huang 
et al., 2012; Hubbert et al., 2002; Tu et al., 2014).  
 
2.3. Immunostaining procedure  
For immunocytochemistry, bEnd.3 cells were cultured on glass cover slips in 24 well 
plates until 90–100% confluence. Cells were then treated with 0.5 and 1 mM of METH 
in the presence or absence of 100 nM TSA or 1 mM ALC, for 24 h. To evaluate a-tubulin, 
cells were washed with PBS, fixed during 10 min in methanol and permeabilized in 0.1% 
Triton X-100 during 10 min. After a blocking of 45 min in 10% NGS (normal goat serum), 
cells were incubated overnight at 4 C with respective primary antibodies – Mouse anti-
a-tubulin (Sigma, clone AA13 IgG1, #T8203, 1:500) and Mouse anti-acetyl-a-tubulin 
(Sigma, clone 6-11B-1 IgG2b, #T7451, 1:500). For secondary antibody incubation we 
used Anti-Mouse IgG Alexa-Fluor 4881 Conjugate (Life Technologies, #A11001, 1:1000) 
for acetylated form and Anti-Mouse IgG Alexa-Fluor 5681 Conjugate (Life Technologies, 
#A11004, 1:1000) for total a-tubulin, for 1 h at room temperature in the dark. Coverslips 
were then mounted onto glass slides with immunomount (Fluorescent Mounting 
Medium, CA, USA) containing 40 ,6-diamidino-2-phenylindole (DAPI), and then 
fluorescence microphotographs were captured using Axio Imager Z1 fluorescence 
microscope (Carl Zeiss, Germany). 
 
2.4. Morphometric analysis  
Changes observed in a-tubulin acetylation by immunofluorescence assays were 
evaluated using the Fiji Software version 2.0. A total of four independent experiments 
were performed. From each coverslip, ten images were blindly captured and analyzed 
through measurement of fluorescence intensity. 
 
2.5. Protein expression analysis by western blot  
Confluent bEnd.3 cells cultured in petri dishes were scrapped and lysed with TEN buffer 
(50 mM Tris–HCl, 2 mM EDTA, 150 mM NaCl, 1% NP-40, supplemented with 
phosphatases and proteases inhibitors) and then centrifuged at 14,000 g for 15 min at 
4 ºC. Protein concentration of the cell lysate was estimated in the supernatant by the 
Bradford method (Bio-Rad Protein Assay, Munich, Germany). Proteins were loaded at 
25mg per lane and resolved by SDS-PAGE on 12% Bis/acrilamide gels and then 
transferred onto PVDF membranes. After blocking with dry milk 5%, membranes were 
incubated with mouse anti-acetyl-a-tubulin antibody (Sigma, clone 6-11B-1 IgG2b, 
#T7451,1:1600). Membranes were washed in Stripping Buffer (RestoreTM Western Blot, 
Thermo Scientific) and then incubated with mouse anti-a-tubulin (Sigma, clone AA13 
IgG1, #T8203, 1:1000). Secondary antibody HRP (horseradish peroxidase)-conjugated 
were used for 1 h of incubation. Chemiluminescent signal detection was achieved using 
the Immun-Star HRP kit (Bio-Rad Laboratories, USA). A GS800 densitometer (Bio-Rad) 
and quantity one 1-D analysis software (v4.6, Bio-Rad) were used for densitometry 
analysis. 
 
2.6. Measurement of HDACs I/II activity 
Evaluation of HDACs activity was performed using HDAC-GloTM I/II Assay and Screening 
System kit (Promega, USA) following provided instructions. This luminescent assay 
measures relative activity of HDAC enzymes using an acetylated luminogenic peptide 
susbstrate. When cleaved the substrate is quantified in a reaction using Ultra-GloTM 
Recombinant Luciferase. Briefly, in each well of 96 multiwell plates, 10,000 bEnd. 3 cells 
were seeded and treated with ALC and TSA in dilution series: ALC (from 2 mM to 0.125 
mM), and TSA (from 500 nM to 3.9 nM). 24 h after treatment, medium was replaced by 
another without phenol red and HDAC buffer was added, followed by HDACTM I/II 
reagent. After an incubation of 30 min, luminescence was measured (Gen5 Data Analysis 
Software, Biotek Instruments, Inc., Synergy 2 (Izasa). 
 
2.7. Real time – PCR 
Total RNA was extracted from confluent bEnd.3 cells grown in petri dishes, using 
RNeasy1 Mini Kit (Qiagen, Hilden, Germany). RNA quality was checked by Experion 
automated electrophoresis system (Bio-Rad Hercules, CA, USA) and cDNA synthesis was 
performed by Qiagen RT2 HT First Strand cDNA kit using 2.0mg of RNA. RT2 SYBR Green 
Mastermix was used to amplify and quantify genes expression on a cycler (Bio-Rad iQ5 
model). Specific primers were designed for gene relative expression of CDKN1A (F: 50 
TGACAGATTTCTATCACTCCAAG30 ; R: 50 TGACCCACAGCAGAAGAG30 ) and HDAC6 (F: 50 
GCAGGAGGCAAGTTGATT30 ; R: 50 AAGAAGGGTGTGGAGTGA30 ). Data were analyzed 
by DDCT method after normalization to GUSB (F: 50 GGTGAAGGTGACAACAACT30 ; R: 
50 CTGAATCCTCGTGCTTATTGA30 ) housekeeping gene expression. 
2.8. Statistical analysis 
Results from at least four independent experiments were represented as mean  SEM. 
Significant differences between groups were determined by one-way ANOVA followed 
by the Sidak’s post hoc test. Significance was set at p < 0.05. All analysis were conducted 
using the software GraphPad Prism1 6.0 for Mac OSX (GraphPad Software, La Jolla, CA). 
3. Results 
3.1. METH decreased a-tubulin acetylation 
The present results show that METH decreased a-tubulin acetylation. 
Immunofluorescence assays were done for both total and acetylated forms of a-tubulin 
showing that when bEnd.3 cells were exposed to METH 1 mM, the amount of the 
acetylated form was significantly reduced (p < 0.01, Fig. 1a and c). No significant 
differences were seen in total a-tubulin (Fig. 1b). This was confirmed by western blot 
analysis where METH 1 mM reduced significantly the rate of acetylated a-tubulin after 
24 h of treatment (p < 0.001, Fig. 1d). 
 
 
 
3.2. ALC effectively prevented METH-induced a-tubulin deacetylation  
In the present study, we addressed the effect of ALC in preventing METH-induced 
deacetylation. Since HDAC6 is responsible for the a-tubulin deacetylation, we used a 
preselected dose of TSA (see Fig. 3a), a strong inhibitor of HDACs activity. Both ALC and 
TSA were able to counteract METH-induced deacetylation, as shown in Fig. 2a and b. 
Our results show that cytoskeleton tubulin from cells pretreated with 1 mM ALC is 
partially protected from METH-induced damage (Fig. 2a and b, p < 0.05, METH 1 mM vs. 
ALC/METH 1 mM). As expected, cells treated simultaneously with TSA and METH 
presented significantly increased acetylation as shown in Fig. 2b (p < 0.001, TSA/METH 
1 mM vs. METH 1 m or vs. the control group). TSA by itself also led to a strong increase 
in a-tubulin acetylation (p < 0.001, TSA vs. control 100 nM). Further testing through 
western blot analysis confirmed these results. TSA 100 nM alone or in combination with 
METH, resulted in a strong acetylation of a-tubulin compared to the control cells or to 
METH-exposed cells (Fig. 2a–c, p < 0.001 for control vs. TSA 100 nM, control vs. TSA/ 
METH 1 mM, and METH 1 mM vs. TSA/METH 1 mM). Pretreatment with ALC 1 mM was 
also seen to be effective in preventing METHinduced deacetylation (Fig. 2c, p < 0.05, 
METH 1 mM vs. ALC/METH 1 mM). ALC by itself did not significantly differ from the 
control (Fig. 2b and c, p = 0.42). 
 
 
 
3.3. ALC is not an effective HDACs inhibitor  
Next, we investigated if ALC could act as a HDACs inhibitor. The effect of TSA, a strong 
inhibitor of HDACs was also assessed. As represented in Fig. 3a, a dose of 100 nM TSA 
inhibits half of the HDACs activity, while a dose of 500 nM reduced activity to near 20%. 
ALC, however does not seem to be able to prevent HDACs activity (Fig. 3b),the 1 mM 
dose seems to provide a slight reduction of HDACs activity, but fails to reach significance 
(p = 0.513, ALC 1 mM vs. control).  
 
 
 
3.4. ALC prevents METH-induced decrease in CDKN1A gene expression 
As ALC does not seem to act as a HDACs inhibitor, we investigated if it could act by down-
regulation of HDAC6 expression levels. However, as represented in Fig. 4a, the 
expression of the HDAC6 gene was not affected by METH or ALC, which seems to 
indicate that METH modulation of HDAC6 occurs at a post-translational level. A common 
marker of HDACs activity is the inhibition of CDKN1A gene expression due to chromatin 
remodeling and condensation (Xu et al., 2007). To evaluate the effect of METH and ALC 
over HDACs activity, we used RT-PCR to assess CDKN1A gene expression levels. As 
expected based on the effects described in Sections 3.1 and 3.2, METH-exposure 
induced a down-regulation of the CDKN1A gene (shown in Fig. 4b, p < 0.001, control vs. 
METH 1 mM). TSA on the contrary, led to an up-regulation of the CDKN1A gene (Fig. 4b, 
p < 0.05, control vs. TSA 100 nM) and prevents the down-regulation induced by METH 
(Fig. 4b, p < 0.001 METH 1 mM vs. TSA/METH 1 mM). Importantly, although ALC by itself 
did not affect the expression of the CDKN1A gene, a pretreatment with ALC was 
effective in preventing METH-induced CDKN1A down-regulation (Fig. 4b, p < 0.001, 
METH vs. ALC/METH 1 mM). 
 
 
 
4. Discussion  
The present work shows that METH considerably reduces a-tubulin acetylation in 
endothelial cells, which is likely to impact cytoskeleton stability, cell motility and 
polarity, and vesicle transport (Hubbert et al., 2002; Matsuyama et al., 2002). 
Importantly, we show that ALC partially prevents METH-induced deacetylation, 
protecting the endothelial cells and consequently preserving the BBB function. 
Cytoskeleton microtubules are regulated by several types of conserved post-
translational modifications (Song and Brady, 2014). Although the biological meaning of 
such mechanisms is still poorly understood, it was reported that tubulin acetylation 
increases its stability and half-life, rendering microtubules more resistant to drug-
induced depolymerization and disassembly (Matsuyama et al., 2002; Szyk et al., 2014). 
Previous studies showed that METH impacts actin filaments, leading to actin 
depolymerization, altered cell shape and local accumulation of condensed actin, which 
may compromise TJs function and BBB integrity (Park et al., 2013; Young et al., 2014). 
Using the bEnd.3 endothelial cell model, we have previously shown that METH-exposure 
led to a dramatic loss of F-actin integrity concomitant with claudin-5 downregulation 
and redistribution (Fernandes et al., 2014). In endothelial cells, these changes at the 
cytoskeleton level may lead to loss of adhesion and/or relevant restructuring of the 
endothelium, thus contributing to METH neurotoxicity. Here, in addition, we show that 
METH reduces microtubule acetylation in endothelial cells. This effect is expected to 
contribute to BBB disruption, since it was previously shown that induced deacetylation 
of microtubules was associated with increased vascular permeability (Bogatcheva et al., 
2007), while augmenting microtubule acetylation seems to be concomitant with the 
inhibition of barrier-disruptive pathways (Gorshkov et al., 2012; Saito et al., 2011). 
HDACs modulation by psychostimulants was previously reported. Exposure of adult rats 
to METH led to altered expression patterns of several HDACs, including HDAC1 and 
HDAC2 (Jayanthi et al., 2014; Martin et al., 2012), and HDAC6, HDAC8-HDAC11, SIRT2, 
SIRT5 and SIRT6 (Omonijo et al., 2014). These expression patterns seem to depend on 
the METH dose and period of exposure. Similarly, cocaine self-administration was 
shown to induce increased expression of several HDACs (Host et al., 2011). In the 
present study, to verify if METH-induced deacetylation of a-tubulin was a result of 
HDACs modulation by METH, we used the HDACs inhibitor TSA (Dompierre et al., 2007). 
Our results evidence that TSA not only prevents METH-induced deacetylation, as it 
strongly promotes a-tubulin acetylation also in METH-exposed endothelial cells. TSA-
mediated hyperacetylation was shown to increase the lifespan of neuronal cultures, and 
a number of studies reported the anti-inflammatory and neuroprotective effects of 
hyperacetylation both in vitro or in vivo models of ischemic stroke (Chuang et al., 2009; 
Harrison and Dexter, 2013) and toxicity (Agudelo et al., 2011). TSA was also used as a 
neuroprotective agent in several models of Parkinsonism (Harrison and Dexter, 2013), 
Huntington’s disease, Alzheimer’s disease and other neurological diseases (Chuang et 
al., 2009). In the oncology context, TSA has been intensively studied. Of note, a recent 
study showed that TSA inhibits cancer invasion through MMPs inhibition associated with 
HDAC2 suppression (Wang et al., 2013). As we have recently shown that METH disrupts 
actin integrity through MMP-9 modulation, it is possible that MMPs inhibition may also 
contribute to prevent METH-induced deacetylation of tubulin. However, as prolonged 
treatment with TSA may lead to neuronal cell toxicity, care should be taken when TSA is 
used for neuroprotective purposes (Chuang et al., 2009). Since we have recently shown 
that ALC counteracts the effect of METH in MMP-mediated toxicity, we have also 
addressed the possible role of ALC in preventing METH-modulation of HDACs. As a 
result, in the present work, we show that 1 mM ALC was able to prevent METH-induced 
deacetylation of a-tubulin. A previous report postulated that ALC had the potential to 
directly inhibit HDACs activity in several cell types possibly by chelating and removing 
Zn2+ from the active site of the HDAC enzyme (Huang et al., 2012). However, here, we 
could not observe a significant effect of ALC on HDACs activity. Of note, the doses used 
by Huang et al. (2012) were 5 and 10 fold higher than the 1 mM dose shown here to 
efficiently prevent tubulin deacetylation. In addition, neither METH nor ALC led to 
altered levels of HDAC6 gene expression, which seems to indicate that both ALC- and 
METH-modulation of HDAC6 activity may occur in a post-translation way, as described 
for TSA (Xu et al., 2007). Despite the previously reported protective properties of ALC 
(Pettegrew et al., 2000), its action at the cytoskeleton level is still poorly explored. We 
have recently shown that ALC effectively prevents METH-induced loss of alignment in 
endothelial actin filaments, through ILK mediated release of MMP-9 (Fernandes et al., 
2014). Of note, ILK was also shown to mediate MMP-9- release through regulation of 
glycogen synthase (GSK)-3b activity (for review see McDonald et al., 2008), while GSK-
3b is known to interact and colocalize with HDAC6, enhancing its activity (Li et al., 2013). 
Since it was reported that ALC antagonizes GSK-3b, arresting microtubule-associated 
protein tau hyperphosphorylation in Alzheimer’s disease (Jiang et al., 2011), it is possible 
that ALC mediation of HDAC6 activity may also occur through GSK-3b inhibition. This 
putative mechanism of action is essentially different from that of TSA that may inhibit 
HDCAs by binding to zinc in their catalytic site (Finnin et al., 1999). In addition to 
hyperacetylation of the respective substrates, HDACs inhibition is also known to lead to 
increased histone acetylation and consequent chromatin remodeling (Li et al., 2013; Xu 
et al., 2007). Under TSA treatment, chromatin relaxation is known to increase the 
expression of CDKN1A (cyclin-dependent kinases inhibitor, or p21) gene (Blagosklonny 
et al., 2002; Hrabeta et al., 2014; Ocker and Schneider-Stock, 2007; Xu et al., 2007). As 
such, CDKN1A (p21) expression is frequently used as a marker of HDAC inhibition 
(Harrison and Dexter, 2013; Huang et al., 2012; Xu et al., 2007). As expected our results 
show that TSA promotes the overexpression of CDKN1A. Opposing to this, in METH-
exposed cells, CDKN1A expression was clearly reduced, which was counteracted by ALC 
and TSA. These results show that in the presence of METH, both ALC and TSA seem to 
maintain CDKN1A expression at levels that are not significantly different from the 
control. However, contrarily to TSA, ALC does not trigger CDKN1A overexpression, which 
has been repeatedly associated with cell cycle arrest, senescence and cell death 
(reviewed by Xu et al., 2007). In that sense, the protection afforded through ALC may be 
more effective and lead to less severe side effects. 
 
 
 
 In summary, we show here for the first time that METH promotes deacetylation of a-
tubulin, which is likely to impact the structure of microtubules at the endothelial cytoskeleton 
and disturb the BBB function. Additionally, we show also that ALC is able to prevent METH-
induced deacetylation, providing effective protection of microtubules acetylation, without 
risking the critical consequences of HDACs inhibition (Fig. 5). Although further investigation is 
still needed, HDACs regulation may become a new therapeutic target for ALC. 
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